BioCentury | Jan 30, 2020
Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current...
BioCentury | Dec 27, 2019
Product Development

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...
BC Week In Review | Dec 1, 2016
Clinical News

Xiaflex: Ph IIa data

A double-blind, U.S. and Australian Phase IIa trial in 75 patients with Dupuytren’s disease and ≥1 palmar nodule showed that a single injection of Xiaflex significantly reduced mean nodule surface area, consistency score and hardness...
BioCentury | Jun 29, 2015
Finance

Arch's golden returns

Mid-month SEC filings show Arch Venture Partners has used two companies with roaring stock prices - Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Receptos Inc. (NASDAQ:RCPT) - to completely pay back LPs in its $400 million seventh fund. A...
BC Week In Review | Sep 1, 2014
Clinical News

Xiaflex: Phase II started

BioSpecifics Technologies started a double-blind, U.S. Phase II trial of Xiaflex in 20 adult patients with >=2 benign lipomas of similar size. Patients will have 1 lipoma treated with Xiaflex, while the other will receive...
BC Innovations | Apr 10, 2014
Tools & Techniques

Toxic assets

A new tool for in vivo detection of liver toxicity could represent a significant improvement over routine methods that only work in vitro or on tissue slices. 1 The litmus test for the Stanford University...
BC Week In Review | Jan 13, 2014
Clinical News

Xiaflex collagenase clostridium histolyticum: Phase II data

Top-line data from an open-label, dose-escalation, U.S. Phase II trial in 14 lipoma patients showed that a single injection of Xiaflex met the primary endpoint of actively reducing the visible surface area of the lipoma...
BC Week In Review | Jan 7, 2013
Clinical News

Cavatak: Interim Phase II data

Interim data from 13 evaluable patients with stage IIIc/IV malignant melanoma in the first stage of a 2-stage, open-label, U.S. Phase II trial showed that 10 intratumoral injections of Cavatak produced 3 objective responses defined...
BC Week In Review | Dec 5, 2011
Company News

PerkinElmer sales and marketing update

PerkinElmer's Caliper company launched Vectra 2 with AQUA technology in North America, Asia and Europe. Caliper partnered with HistoRx Inc. (New Haven, Conn.) in March to develop the immuno-fluorescence imaging technology to measure proteins in...
BC Week In Review | Nov 14, 2011
Company News

Caliper, PerkinElmer deal

PerkinElmer completed its acquisition of fellow life sciences supply company Caliper for $10.50 per share, or about $600 million in cash (see BioCentury, Sept. 12). Caliper Life Sciences Inc. , Hopkinton, Mass.   PerkinElmer Inc. (NYSE:PKI),...
Items per page:
1 - 10 of 226
BioCentury | Jan 30, 2020
Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current...
BioCentury | Dec 27, 2019
Product Development

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...
BC Week In Review | Dec 1, 2016
Clinical News

Xiaflex: Ph IIa data

A double-blind, U.S. and Australian Phase IIa trial in 75 patients with Dupuytren’s disease and ≥1 palmar nodule showed that a single injection of Xiaflex significantly reduced mean nodule surface area, consistency score and hardness...
BioCentury | Jun 29, 2015
Finance

Arch's golden returns

Mid-month SEC filings show Arch Venture Partners has used two companies with roaring stock prices - Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Receptos Inc. (NASDAQ:RCPT) - to completely pay back LPs in its $400 million seventh fund. A...
BC Week In Review | Sep 1, 2014
Clinical News

Xiaflex: Phase II started

BioSpecifics Technologies started a double-blind, U.S. Phase II trial of Xiaflex in 20 adult patients with >=2 benign lipomas of similar size. Patients will have 1 lipoma treated with Xiaflex, while the other will receive...
BC Innovations | Apr 10, 2014
Tools & Techniques

Toxic assets

A new tool for in vivo detection of liver toxicity could represent a significant improvement over routine methods that only work in vitro or on tissue slices. 1 The litmus test for the Stanford University...
BC Week In Review | Jan 13, 2014
Clinical News

Xiaflex collagenase clostridium histolyticum: Phase II data

Top-line data from an open-label, dose-escalation, U.S. Phase II trial in 14 lipoma patients showed that a single injection of Xiaflex met the primary endpoint of actively reducing the visible surface area of the lipoma...
BC Week In Review | Jan 7, 2013
Clinical News

Cavatak: Interim Phase II data

Interim data from 13 evaluable patients with stage IIIc/IV malignant melanoma in the first stage of a 2-stage, open-label, U.S. Phase II trial showed that 10 intratumoral injections of Cavatak produced 3 objective responses defined...
BC Week In Review | Dec 5, 2011
Company News

PerkinElmer sales and marketing update

PerkinElmer's Caliper company launched Vectra 2 with AQUA technology in North America, Asia and Europe. Caliper partnered with HistoRx Inc. (New Haven, Conn.) in March to develop the immuno-fluorescence imaging technology to measure proteins in...
BC Week In Review | Nov 14, 2011
Company News

Caliper, PerkinElmer deal

PerkinElmer completed its acquisition of fellow life sciences supply company Caliper for $10.50 per share, or about $600 million in cash (see BioCentury, Sept. 12). Caliper Life Sciences Inc. , Hopkinton, Mass.   PerkinElmer Inc. (NYSE:PKI),...
Items per page:
1 - 10 of 226